New hope for XLRP patients; gene therapy may slow or cure vision loss.
Read More »
Accorda Therapeutics receives Refusal to File letter for Inbrija
Abbott to begin clinical study of Amplatzer device
BioMarin's pegvaliase accepted for FDA priority review
Biologics selected as distributor for Pfizer's Besponsa
Trovagene reports on drug targeting Non-Hodgkin Lymphoma cell lines